BACKGROUND: Myeloma survival varies markedly with International Staging System classification, presence of cytogenetic abnormalities, and, especially, gene expression profiling-based risk and delTP53 status, whose collective impact has not been examined in the context of specific therapies. METHODS: The authors examined overall survival (OS), event-free survival (EFS), and complete response duration (CRD) in Total Therapy 2 with randomization to a control or thalidomide arm and in Total Therapy 3 with added bortezomib. Among 612 patients with complete data sets, multivariate analyses were used to investigate the relative contributions to OS, EFS, and CRD of International Staging System stage, cytogenetic abnormalities, and gene expression profiling-derived risk and delTP53 status, in the context of the 3 Total Therapy regimens. RESULTS: Whereas gene expression profiling risk segregated outcomes within all 3 International Staging System stages, International Staging System 3 conferred inferior prognosis only in low-risk myeloma, whereas the grave prognosis of high-risk disease was International Staging System-independent. After adjusting for gene expression profiling-defined high risk and delTP53 in multivariate analysis, International Staging System 3 and cytogenetic abnormalities both retained independent adverse implications for OS, EFS, and CRD. Among the 86% with low-risk disease, cytogenetic abnormalities and delTP53 both affected all 3 endpoints negatively, whereas the International Staging System 3 effect was limited to OS. Total Therapy 3 improved survival outcomes beyond results obtained with Total Therapy 2. CONCLUSIONS: In the genomic era, standard laboratory variables, such as International Staging System stage and presence of cytogenetic abnormalities, continue to impact survival after adjusting for gene expression profiling risk and delTP53 status, providing a basis for stratification in our current practice of gene expression profiling risk-based treatment assignment.
BACKGROUND:Myeloma survival varies markedly with International Staging System classification, presence of cytogenetic abnormalities, and, especially, gene expression profiling-based risk and delTP53 status, whose collective impact has not been examined in the context of specific therapies. METHODS: The authors examined overall survival (OS), event-free survival (EFS), and complete response duration (CRD) in Total Therapy 2 with randomization to a control or thalidomide arm and in Total Therapy 3 with added bortezomib. Among 612 patients with complete data sets, multivariate analyses were used to investigate the relative contributions to OS, EFS, and CRD of International Staging System stage, cytogenetic abnormalities, and gene expression profiling-derived risk and delTP53 status, in the context of the 3 Total Therapy regimens. RESULTS: Whereas gene expression profiling risk segregated outcomes within all 3 International Staging System stages, International Staging System 3 conferred inferior prognosis only in low-risk myeloma, whereas the grave prognosis of high-risk disease was International Staging System-independent. After adjusting for gene expression profiling-defined high risk and delTP53 in multivariate analysis, International Staging System 3 and cytogenetic abnormalities both retained independent adverse implications for OS, EFS, and CRD. Among the 86% with low-risk disease, cytogenetic abnormalities and delTP53 both affected all 3 endpoints negatively, whereas the International Staging System 3 effect was limited to OS. Total Therapy 3 improved survival outcomes beyond results obtained with Total Therapy 2. CONCLUSIONS: In the genomic era, standard laboratory variables, such as International Staging System stage and presence of cytogenetic abnormalities, continue to impact survival after adjusting for gene expression profiling risk and delTP53 status, providing a basis for stratification in our current practice of gene expression profiling risk-based treatment assignment.
Authors: Mauricio Pineda-Roman; Maurizio Zangari; Jeff Haessler; Elias Anaissie; Guido Tricot; Frits van Rhee; John Crowley; John D Shaughnessy; Bart Barlogie Journal: Br J Haematol Date: 2008-03 Impact factor: 6.998
Authors: Philip R Greipp; Jesus San Miguel; Brian G M Durie; John J Crowley; Bart Barlogie; Joan Bladé; Mario Boccadoro; J Anthony Child; Herve Avet-Loiseau; Jean-Luc Harousseau; Robert A Kyle; Juan J Lahuerta; Heinz Ludwig; Gareth Morgan; Raymond Powles; Kazuyuki Shimizu; Chaim Shustik; Pieter Sonneveld; Patrizia Tosi; Ingemar Turesson; Jan Westin Journal: J Clin Oncol Date: 2005-04-04 Impact factor: 44.544
Authors: John D Shaughnessy; Fenghuang Zhan; Bart E Burington; Yongsheng Huang; Simona Colla; Ichiro Hanamura; James P Stewart; Bob Kordsmeier; Christopher Randolph; David R Williams; Yan Xiao; Hongwei Xu; Joshua Epstein; Elias Anaissie; Somashekar G Krishna; Michele Cottler-Fox; Klaus Hollmig; Abid Mohiuddin; Mauricio Pineda-Roman; Guido Tricot; Frits van Rhee; Jeffrey Sawyer; Yazan Alsayed; Ronald Walker; Maurizio Zangari; John Crowley; Bart Barlogie Journal: Blood Date: 2006-11-14 Impact factor: 22.113
Authors: M Pineda-Roman; M Zangari; F van Rhee; E Anaissie; J Szymonifka; A Hoering; N Petty; J Crowley; J Shaughnessy; J Epstein; B Barlogie Journal: Leukemia Date: 2008-04-24 Impact factor: 11.528
Authors: Bart Barlogie; Guido Tricot; Elias Anaissie; John Shaughnessy; Erik Rasmussen; Frits van Rhee; Athanasios Fassas; Maurizio Zangari; Klaus Hollmig; Mauricio Pineda-Roman; Choon Lee; Giampaolo Talamo; Raymond Thertulien; Elias Kiwan; Somashekar Krishna; Michele Fox; John Crowley Journal: N Engl J Med Date: 2006-03-09 Impact factor: 91.245
Authors: Sarah K Johnson; Christoph J Heuck; Anthony P Albino; Pingping Qu; Qing Zhang; Bart Barlogie; John D Shaughnessy Journal: Int J Hematol Date: 2011-10-15 Impact factor: 2.490
Authors: Gunjan L Shah; Heather Landau; Dory Londono; Sean M Devlin; Satyajit Kosuri; Alexander M Lesokhin; Nikoletta Lendvai; Hani Hassoun; David J Chung; Guenther Koehne; Suresh C Jhanwar; Ola Landgren; Ross Levine; Sergio A Giralt Journal: Leuk Lymphoma Date: 2017-01-12
Authors: A Krishnan; P Kapoor; J M Palmer; N-C Tsai; S Kumar; S Lonial; M Htut; C Karanes; N Nathwani; M Rosenzweig; F Sahebi; G Somlo; L Duarte; J F Sanchez; D Auclair; S J Forman; J G Berdeja Journal: Leukemia Date: 2017-12-18 Impact factor: 11.528
Authors: Patrick W Mellors; Moritz Binder; Rhett P Ketterling; Patricia T Greipp; Linda B Baughn; Jess F Peterson; Dragan Jevremovic; Kathryn E Pearce; Francis K Buadi; Martha Q Lacy; Morie A Gertz; Angela Dispenzieri; Suzanne R Hayman; Prashant Kapoor; Wilson I Gonsalves; Yi L Hwa; Amie Fonder; Miriam Hobbs; Taxiarchis Kourelis; Rahma Warsame; John A Lust; Nelson Leung; Ronald S Go; Robert A Kyle; S Vincent Rajkumar; Shaji K Kumar Journal: Blood Adv Date: 2020-05-26
Authors: Rowan Kuiper; Mark van Duin; Martin H van Vliet; Annemiek Broijl; Bronno van der Holt; Laila El Jarari; Erik H van Beers; George Mulligan; Hervé Avet-Loiseau; Walter M Gregory; Gareth Morgan; Hartmut Goldschmidt; Henk M Lokhorst; Pieter Sonneveld Journal: Blood Date: 2015-09-01 Impact factor: 22.113